Delhi School Of Public Health & Dr B. R. Ambedkar Center For Biomedical Research, University of Delhi organised an Interactive Webinar “On Truths and Myths of Covid 19”, on 13.8.2020. Dr K K Agarwal, Padam Shri Awardee , President HCFI & CMAAO addressed the gathering
One day International Webinar was organized by DSPH along with ACBR and Miranda House on ‘Breast Cancer awareness : Be aware, Be safe’ on 24.10.2020. The symposium included E-posters presentation, video making competition and panel discussion. The speakers includedDr Anil Shankar, Dept of Biochemistry, School of Medicine, Meharry Medical College, Tannessee, USA Dr Navita Somaiah, Consultant Oncologist & Team leader, The Institute of Cancer Research & Royal Marsden Hospital, UK Dr Kachan Kaur, Director Breast surgery, Cancer Institute of Medanta, The Medicity, Gurugram, India
Talks given at various Institutes by Prof RNK Bamezai, Director, Delhi School of Public Health:
Bamezai, RNK: Speaker at the PANEL DISCUSSION in the International Conference on AYUSH in Public Health Including Covid 19 Management; April 16 & 17, 2022. Jeevaniya Society & Mission Samriddhi; Partners: Ministry of AYUSH, GOI, Delhi; CSIR- CIMAP, NBRI, & PWA, Lucknow, IASTAM, Arogya Bharati, Vishwa Ayurved Parishad, HMAI, AIUT Congress & CISSA, Bengaluru, on: “Regulations and Policies for promotion of AYUSH in Public Health, Moderator: Dr V M Katoch, Former DG, ICMR, New Delhi.
ABSTRACT: APPROACH FOR R&D IN AYUSH AND LOCAL HEALTH TRADITIONS (LHTs) FOR PROMOTING PUBLIC HEALTH
BACKGROUND: Role of AYUSH, especially Ayurvedic regimens (Rasayanas and Non-rasayanas), in the prophylaxis and clinical management of asymptomatic, mild and moderate COVID-19 cases, has reposed faith in the traditional system of medicine for health-care and wellness. Attributed to potentiation of immune-response and a build-up towards immune-competence, the phytochemicals provide Bala, Vyadi Kshamathwa, ojas; apparently working in a customised and personalised manner. Both these features (immune potentiation and personalised medicine) associated with Ayurved (and AYUSH) provide a baseline for future R&D to unravel the mechanism of action, using modern medical-biology tools to understand the Personalised and Prakriti (Dosha) based clinical heterogeneity in Nija (imbalance within one’s own body) and Aganthu (caused by an external factor) disease categories. Thus, the spirit of universal Public Health and Wellness lies inherently in the conceptual framework of AYUSH.
The ease with which `proven good practices` get universalised and integrated in the on-going Allopathy practices of health-care and wellness, depends on how policies are shaped and validation procedures are strengthened. For this, understanding of the mechanism of action and the personalized-customized character of AYUSH needs detailed experimental work out. Leads, in turn, shall provide a universal scientific language to communicate and convince anyone globally.
R&D ROAD-MAP: Progress in the knowledge base, tools and techniques in modern medical biology, has allowed to unravel the mechanistical details about the role of phytopharmaceuticals in different metabolic responses, capacities, physiological and pharmacological differences at genomic and metabolic levels, and the signaling mechanisms. Added to this, the inclusion of an appropriately Chemotyped and well characterized plant source is equally important. Finally, the possibility of the huge data set generated is analyzed with machine learning, artificial intelligence and other tools, for application in precise characterization of patients, and their cusotomized intervention and prevention. Researching and simplifying the high-end-high-throughput-OMICS-technologies and make these affordable and cost-effective has to be the goal for future Public Health services (DOI: https://doi.org/10.29195/DSSS.03.01.0036).
Steps in this direction though visible over the past decade or so; need to be designed meticulously and comprehensively, without loosing out on the axioms and principles inherent to the traditional system, lest we fail. For this, `Documenting-with-Evidence-Approach` the potential to cure or prevent a set of diseases and disorders; and assessing the `Practices (LHTs) of Wellness in Health-Care`, is essential for an appropriate R&D input. Aligning Tridosha profiles with OMICS-technologies-based-signatures and Immunological readouts, and creating a matrix with AYUSH based treatment for a given disease would set the tone for mechanistic understanding of the disease in the studied cohort, a step towards validation of the traditional approach adopted. Picking-up success stories, in diseases of choice (ranging from Arthritis, Allergy, Asthma, Hypertension, Type2 Diabetes, Anxiety, Digestive and Skin related problems, and many more complex diseases) and mining these deeply with diverse OMICS approaches and Immunological readouts, would bring out the requisite support to the age old practice of AYUSH.
Operationalizing the R&D base, as suggested, requires coordination between AYUSH hospitals and Centres of Excellence and Modern Medical Biology Centres of excellence. In India, creating and efficiently managing the essential basic health-care infrastructure has been a challenge in populous and culturally diverse country (DOI: https://doi.org/10.29195/DSSS.03.01.0039). Strengthening the affordable AYUSH based System, and making it modern and efficient shall provide answers to universal health care. The knowledge generated should not end only in publications, and has to be in-sync with the molecular epidemiology characterization of a disease and its precise and well-understood intervention through AYUSH for public health. Easy dissemination, skilled trained man-power, and a strong integrated network with an empathetic and holistic health-care delivery machinery and approach is vital.
RNK Bamezai. Chief Guest. Centenary Seminar Series, Dr. B.R.Ambedkar Centre for Biomedical Research for ACBR Virtual Keynote Lecture on "Advanced multiomics system biology analyses to understand progressive immune disruption in COVID-19" by Dr. Ujjwal Neogi, Karolinska Institute, Stockholm, Sweden. January 24, 2022.
RNK Bamezai: Key-Note speaker in the online Faculty Development Program on MOOCs and E-learning in context of National Education Policy. Organized by Delhi School of Public Policy and Governance (DSPPG), IoE, DU on October 18, 2021.
RNK Bamezai: Professional Development and Skill Enhancement of Lab. Staff organized by DU on September 8, 2021
RNK Bamezai: Challenges in Screening for Genetic Disorders in India. Organized by GAP Health Foundation and UCOST, Uttarakhand virtually. September 21, 2020.
RNK Bamezai: National Sickle Cell Conclave. World Sickle Cell Day (WSCD) June 19th, 2020. Participated in the Virtual Panel Discussion on Multiple Faces of SCD. Organized by FICCI and inaugurated by the then Minister Rural Dev.
Talks given at various Institutes by Prof Daman Saluja, Jt Director, Delhi School of Public Health:
“Ethics in research”, inaugural talk given on 24.10.2020 at International Webinar Series on Research Integrity and Ethics, organized by Bhaskaracharya College of Applied Science, University of Delhi.
‘Lessons learnt from COVID 19’ at one day Webinar on 21.01.2021 organised by CATHEXIS, society of Acharya Narender Dev College, University of Delhi.
Role of Long non-coding RNA (LnRNA) in suppression of invasion and metastasis in colon cancer on Webinar organized by Department of Biotechnology, Pondicherry University on 26.2.2021
Understanding the role of p73 in suppression of invasion and metastasis in colon carcinoma Webinar organised by Department of Biotechnology, Delhi Technical University on 11.2.21
Development of novel therapeutic strategy against Cancer: Targeting stem cell differentiation by natural compound at Hindu college, University of Delhi on 04.1.2022
Nucleic acid-based diagnostic assays and their application in health sciences at SRCASW, University of Delhi 3.2.2022
Chaired the session on ‘Cancer causation & Biomarkers’ on 24 th Feb 2022, in the conference 2 nd International RMBPD Colloquium on “Deciphering Bioregulatory Mechanisms in Health and Disease using ‘Omics’ Approach” from February 24-25, 2022 to commemorate the 100 th year of University of Delhi and 75 th year of the Department’s existence
Development of novel therapeutic strategies against Cancer: Targeting stem cell differentiation by natural compound, Esculetin. 41 st Annual Conference of the Indian Association for Cancer Research (IACR-2022) on “Combating Cancer: Biology to Therapy to Drug Resistance” along with an International Symposium on “Stem Cell and Cancer” which is being organized by Amity Institute of Molecular Medicine & Stem Cell Research (AIMMSCR), Amity University, Uttar Pradesh, Noida from 2 nd to 5 th March 2022.
Insights into structural determination studies of CB1 receptor as a means to understand their signaling mechanism in diseasesThe cannabinoid type 1 receptor (CB1R) is the most abundant G protein-coupled receptor (GPCR) in the mammalian central nervous system. CB1 signaling exerts important physiological functions, including retrograde inhibition of neurotransmitter release, control of neuronal excitability and regulation of various forms of long-term synaptic plasticity. In this JC, we reviewed the various approaches taken till date to solve the structure of this elusive target for drug discovery, and therein identify the missing links. Cryo-EM has immensely enhanced the 3D structure determination of protein complexes. The latest 3.00 Å CB1 cryo-EM structure (PDB: 6N4B) by Krishna Kumar et al. (Cell 2019), confirmed their fundamental seven transmembrane (TM) helical architecture, probable binding pocket for FUB (high affinity synthetic agonist), pertinent structural changes in -heterotrimeric Gi protein complex, intracellular loop (ICL2), TM1 and TM7 to accommodate FUB indicate high degree of plasticity exhibited by these receptors. This emphasizes the need for structural studies detailing missing links such as the C-Terminal end of CB1. It is only then, the true regulation of the transducing mechanisms mediated by interactors of CB1 can be illustrated.
Journal Club: "Neurodegeneration: A Mathematical Point of View", 8 April 2022 by Dr. Vishal Singh, DSPH-IoE, DUProtein aggregation begins with partially folded segment of the protein which acts as monomer. A series of sequential and parallel events such as protein-protein interactions, local structure perturbation and negative consequences of the environment help the evolution of the initial component i.e. dimer or nucleus/oligomer, which subsequently polymerizes and eventually forms the amyloid fibrils or aggregates due to sedimentation. A unique mechanism that defines the formation of aggregates or amyloid fibrils is not yet clear, but the nucleation and growth mechanism is widely supported by most of the experimental and theoretical models. In this context, Knowles and Dobson group (Science, 326, 1533, 2009 [https://www.science.org/doi/10.1126/science.1178250]) presented an analytical treatment of a set of coupled kinetic equations that governs the self-assembly of filamentous molecular structures. Their results reveal a range of general features of the growth kinetics of fragmenting filamentous structures. Since protein aggregation is the hallmark of a wide variety of debilitating disorders like Alzheimer’s, Parkinson’s, Amyotrophic lateral sclerosis (ALS), Huntington’s, Creutzfeldt-Jakob’s disease and dementia, a effective therapeutic strategies is crucial to prevent these protein aggregation processes. In this way, these group (PNAS, 117, 24251-24257, 2020 [https://www.pnas.org/doi/10.1073/pnas.2006684117]) shown a general theory of aggregation kinetics in the presence of an inhibition. These results provide general physical laws to guide the design and optimization of inhibitors of amyloid fibril formation. The mathematical tools available are extremely useful for designing the inhibitors to prevent the aggregation process.
Journal Club : The origin of leukemic stem cells, April 1, 2022 by Dr. Ankit MathurLeukemic is a heterogeneous condition in which therapy resistant leukemic stem cells contribute to the relapse of the disease. In this JCS discussed the origin of leukemic stem cells that may provide information of leukemogenesis as well as developing new therapeutic targets for a possible complete remission of leukemia.